Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Abstract: The present application relates to a fusion protein comprising: an antibody or antigen-binding fragment thereof that binds to C3b; and a polypeptide that binds to C3b, wherein the polypeptide comprises: (i) the amino acid sequences according to SEQ ID NO: 11 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 11; and (ii) the amino acid sequences according to SEQ ID NO: 12 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12, wherein the antibody or antigen-binding fragment thereof of the fusion protein does not compete for binding to C3b with the polypeptide of the fusion protein. The application also provides polypeptides, nucleic acids, vectors and methods of preparing these as well as methods of treatment and pharmaceutical compositions.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well 5 as methods of treating disorders associated with complement activation.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well 5 as methods of treating disorders associated with complement activation.